What is the role of ethics committees after Regulation (EU) 536/2014?
EU Regulation 536/2014 stipulates that when assessing applications for authorisation to conduct clinical trials, Member States should formulate a ‘single decision’. This raises the problem of identifying: (1) the facility designated to express this ‘single decision’ and (2) the role of ethics commit...
Main Author: | |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
BMJ Publ.
2016
|
In: |
Journal of medical ethics
Year: 2016, Volume: 42, Issue: 3, Pages: 186-188 |
Standardized Subjects / Keyword chains: | B
Europäische Union, Verfasserschaft1, Verordnung über klinische Prüfungen mit Humanarzneimitteln
/ Ethics committee
|
Online Access: |
Volltext (JSTOR) Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
Summary: | EU Regulation 536/2014 stipulates that when assessing applications for authorisation to conduct clinical trials, Member States should formulate a ‘single decision’. This raises the problem of identifying: (1) the facility designated to express this ‘single decision’ and (2) the role of ethics committees in the decision-making process. The article addresses the consequences of the requirement that for each Member State the assessment of an application for approval to conduct a trial must take the form of a ‘single decision’ by the Member State concerned. Three possible approaches to the procedures for expressing that ‘single decision’ and to the role of ethics committees in the decision-making process are described, one of which is indicated as the preferred option. |
---|---|
ISSN: | 1473-4257 |
Contains: | Enthalten in: Journal of medical ethics
|
Persistent identifiers: | DOI: 10.1136/medethics-2015-103028 |